Good R&D leadership is knowing when to keep investing in a development program, when to change course, and when to return to ...

Precision oncology only works when biomarker testing helps identify the right patients before launch, explains Boehringer ...

Patrick Mooney, CEO of SpyGlass Pharma, shares how insights from the cockpit have shaped his approach to leading an innovative biotech.

Nasdaq’s new $5 million MVLS rule raises delisting risk for micro-cap life sciences companies, making exchange choice an ...

On this weeks episode of the Business of Biotech, Omar Khalil, Managing Director at Santé Ventures, describes forming and funding startups and early-stage biotech companies with a focus on clinical ...

The North Carolina Biotechnology Center leads life sciences economic development for North Carolina by supporting the progression of ideas from research lab to the marketplace. NCBiotech invests in ...

Biotech’s old risk-sharing model is breaking down, forcing academia, investors, pharma, and healthcare systems to collaborate earlier to bring cures to patients.

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...

In a few short years, Novo Nordisk has gone from belt-tightening to parachute pants, and is now replaying a GLP-1 competition with Eli Lilly that kicked off with Victoza and Trulicity ten years ago.

Industry Explorers Blaze On: A series of stories of longtime leaders, still active in the industry, sharing their historical perspectives on life sciences industry innovation. A consuming interest, ...

Individualized genetic medicine is moving faster than the traditional drug approval model was built to handle. Genome editing, RNA-based medicines, and other targeted therapies can now be designed for ...

As pharmaceutical manufacturers grow, they often pursue external sources of innovation to supplement their own R&D efforts. A recent study found that 45% of drugs in the pipelines of 20 large ...